Latest Health News

4DMedical has responded to ASX queries over its FY2025 financial report, clarifying assumptions behind intangible asset valuations and addressing the auditor’s qualified opinion.

Mesoblast is set to meet the FDA in December to discuss compelling Phase 3 data showing its cell therapy rexlemestrocel-L may significantly reduce opioid use in chronic low back pain patients. This meeting could mark a pivotal step in addressing the US opioid crisis through innovative regenerative medicine.

Stakk Limited has reported a record-breaking $575,000 in revenue for October 2025, marking a staggering 146% increase from the previous month and nearly 9,500% growth year-over-year.

BPH Global has locked in a six-month exclusive agreement to evaluate a proprietary ginseng-based formulation aimed at enhancing male vitality, signaling a strategic push into Traditional Chinese Medicine-inspired wellness products.

TPG Telecom has announced a substantial special dividend and capital reduction totaling approximately AUD 3 billion, pending shareholder approval at the upcoming EGM.

Nanosonics Limited has announced a $20 million on-market share buy-back program for FY26, underscoring its robust financial health and confidence in future growth driven by new product innovations.

CSL Limited’s latest Capital Markets Day presentation highlights CSL Seqirus’s strategic positioning to capitalize on a recovering US influenza vaccine market and global growth opportunities.

Orthocell has appointed a second Canadian distributor for its nerve repair device Remplir™, achieving full national coverage and setting the stage for initial sales this quarter.

TrivarX Limited has exercised its option to acquire the innovative Stabl-Im brain imaging technology, aiming to revolutionize early detection of brain tumours pending shareholder approval.

Medibank is set to acquire Better Medical, a network of 61 GP clinics across four states, for approximately $159 million, enhancing its primary care footprint and preventive health initiatives.

Mayne Pharma updates shareholders on the extended Foreign Investment Review Board approval deadline and the rescheduled court hearing for its acquisition scheme by Cosette Australia BidCo.

Brightstar Resources has enhanced its leadership team with seasoned mining executives and is advancing its Sandstone project, targeting a resource upgrade in early 2026 as it pursues a +200,000-ounce annual gold production goal.